Background Animal data indicate that ATP derived from aggregating thrombocytes or endothelium induces an endothelium-dependent vasodilator response that is mediated by P2,-purinergic receptors and is reduced when high dosages are administered. This reduced vasodilator response to high ATP doses has been associated with the concomitant release of endothelium-derived contracting factors. In contrast to the endothelium-dependent vasodilator response, ATP as released from sympathetic nerve endings induces a P2,,-purinergic receptor-mediated vasoconstrictor response that may contribute to the attenuated vasodilator response to high dosages of luminally applied ATP. The dual action of ATP might be important in the pathophysiology of disease states characterized by an impaired endothelial function and increased thrombocyte aggregation. This study was performed to characterize the vascular response to ATP in humans.
Methods and Results The brachial artery was cannulated in 50 healthy male volunteers (age, 18 to 44 years) for drug infusion and measurement of mean arterial pressure. Forearm blood flow was recorded by venous occlusion strain-gauge plethysmography. ATP induced a dose-dependent vasodilator response that was significantly higher than the effect of equimolar adenosine infusion and that was not reduced by concomitant infusion of the P,-purinergic receptor antagonist theophylline. The 40 .8±7.3% for acetylcholine, ATP, and SNP pretreatment, respectively (P<.01 for acetylcholine versus ATP and SNP; P>.1 for ATP versus SNP). In contrast to animal data, high dosages of intra-arterially infused ATP (up to 1000 jig. 100 mL forearm`' . min-') did not reveal a reduction in the forearm vasodilator response but appeared to be similar to the maximal forearm vasodilation as observed during postocclusive reactive hyperemia. Conclusions These observations indicate that ATP induces a potent dose-dependent vasodilator response that is not mediated by P,-purinergic receptor stimulation or by the release of nitric oxide. Moreover Pi-purinergic receptor stimulation, P,-purinergic receptors are subdivided into Al-and A2-adenosine receptors. 4 In the vascular wall, A2-adenosine receptors, located on endothelial and smooth muscle cells, are involved in the vasodilator response to adenosine.5 On sympathetic nerve endings, stimulation of the A,-adenosine receptor results in a reduced release of norepinephrine. 6 Methylxanthines like theophylline and caffeine are competitive antagonists on both P,-purinergic receptor subtypes. [7] [8] [9] Recently, this subdivision has been confirmed by molecular techniques.10 After approval from the local ethics committee, a total of 50 healthy male volunteers signed written informed consent statements before participation in the study. Their demographic characteristics are summarized in Table 1 . Before the start of the study, the subjects were asked to abstain from caffeinecontaining products for at least 36 hours and to refrain from smoking for at least 12 hours. Furthermore, subjects were asked to discontinue any food intake 2 hours before the start of the experiment. All experiments were performed in the afternoon with the subject in the supine position. After In 12 subjects, the vasodilator effect of equimolar dosages of intra-arterially infused adenosine and ATP were compared. Additionally, the effect of intra-arterially infused theophylline, a competitive P1-purinergic receptor antagonist, on the vasodilator response to ATP was studied. The experiment started with the measurement of baseline FBF during saline infusion (NaCl 0.9%). Fig 1 shows the course of FBF and the schedule of the several drug infusions. The effect of two increasing dosages of adenosine (0.5 and 1.5 ,ug * 100 mL forearm-1 . min-1, equivalent to 2 and 6 nmol* 100 mL-. min-1) was compared with that of saline infusion. Fifteen minutes after the last adenosine infusion, saline was infused again. Now, the effect of four increasing dosages of ATP (0.1, 0.3, 1.0, and 3.0 ,gg 100 mL forearm`. min-1, equivalent to 0.2, 0.6, 2, and 6 nmol* 100 mL forearm`1 . minm1) were compared with saline infusion. Because prolonged occlusion of hand circulation can cause discomfort, with subsequent effects on BP and heart rate (HR), a 10-minute rest was allowed between the second and third ATP infusions. Forty-five minutes after the last ATP infusion, saline infusion and the four increasing ATP dosages were repeated in six subjects ("time-control study"). In the other six subjects, saline infusion and the four increasing ATP dosages were repeated with concomitant infusion of theophylline (100 ,ug. 100 mL Adenosine was infused at a rate of 2 and 6 nmol * 100 mL forearm-' * min-1, and ATP was infused at rates of 0.2, 0.6, 2, and 6 nmol * 100 mL forearm-' * min-l. Involvement of NO in ATP-Induced Forearm Vasodilator Response
We studied the effect of intra-arterially infused N0-monomethyl-L-arginine (L-NMMA), a competitive NO synthase antagonist, on the vasodilator response to ATP (N= 10), to the NO-dependent vasodilator acetylcholine (N=10), and to sodium nitroprusside (SNP, N=6), an NO donor that does not stimulate NO synthase activity.25 Acetylcholine, a proven NO-dependent vasodilator in the human forearm,26,27 was used to ascertain the effectiveness of our experimental setup to demonstrate antagonistic properties of L-NMMA (positivecontrol experiment). L-NMMA reduced FBF, which might nonspecifically affect the subsequent response to a vasodilator stimulus. Therefore, the interaction between SNP and L-NMMA was also studied (negative-control experiment). Apart from the effect of L-NMMA on the aforementioned vasodilator response to acetylcholine, ATP, and SNP, the forearm vasoconstrictor response to L-NMMA itself was analyzed to find out whether this was related to the effect of the previously infused vasodilator substances on NO synthase.
The experiment started with the measurements of baseline FBF during saline infusion. The effects of three increasing dosages of ATP (0.3, 3, and 10 ,gg 100 mL forearmnf min-l') were compared with that of saline infusion. Because prolonged occlusion of hand circulation can cause discomfort, with subsequent effects on BP and HR, a 10-minute rest was allowed between the first and second ATP infusions. Forty-five minutes after the last ATP infusion, the vasoactive effect of L-NMMA infusion (0.1 mg* 100 mL forearm' min-1) was compared with that of saline infusion. Subsequently, the lowest ATP dose was infused (0.3 gg* 100 mL forearm' min-') together with infusion of L-NMMA (0.05 mg* 100 mL forearmn' * min-'). Ten minutes thereafter, L-NMMA was infused again (0.1 mg. 100 mL forearm' min-'), immediately followed by the middle and the highest ATP dosages (3 and 10 ugg 100 mL forearm' * minir), again together with the lower L-NMMA dose (0.05 mg* 100 mL forearm *. min-1). In the acetylcholine group, acetylcholine (0.5, 2, and 8 ,gg 100 mL forearml min-1) was substituted for ATP. In the SNP group, SNP (0.02, 0.2, and 0.6 ,gg 100 mL forearm . * min-') was substituted for ATP. Since SNP is diluted in glucose 5%, in the SNP group, glucose 5% was substituted for NaCi 0.9%. Otherwise, the same protocol was performed in the three groups. and release of EDCFs may be involved in this response. To study these possible mechanisms in humans, the effects of high dosages of intra-arterially infused ATP were studied in 12 subjects. The effects of four increasing intra-arterially infused ATP dosages (10, 30, 100, and 300 ,gg 100 mL forearm`. min-1) were compared with that of saline infusion. To avoid discomfort, a 10-minute rest was allowed between the second and third ATP infusions. After the first 6 experiments, an interim analysis was performed, revealing no decreased vasodilator response at the highest dosage. In the subsequent 6 experiments, 1000 ,tg ATP. 100 mL forearm'. min-1 was infused immediately after the fourth ATP infusion. To be sure that maximal vasodilation occurred in response to the ATP infusions, maximal vasodilation was measured during postocclusive reactive hyperemia according to the well-established method of Pedrinelli et al.30'31 A cuff applied to the left upper arm was inflated to 300 mm Hg for 13 minutes. During the last minute of ischemia, the subjects were asked to perform repeated hand contractions. Immediately after desufflation of the upper-arm cuff, FBF measurements were started for at least 2 minutes with occluded hand circulation. The lowest forearm vascular resistance (MAP/FBF) was considered to represent maximal vasodilation.
Drugs and Solutions
ATP solutions were freshly prepared from 2-mL ampoules containing 20 mg ATP as disodium salt (Striadyne, Wyeth Laboratories) and were diluted in NaCl 0.9%. L-NMMA acetate and acetylcholine chloride (Sigma Chemical Co) were reconstituted on the morning of the study day from a sterile lyophilized powder, passed through a 0.2-,um Millipore filter, and diluted in NaCl 0.9%. Adenosine (Sigma) was freshly prepared from 10-mL ampoules containing 20 mg adenosine with NaCl 0.9% as solvent. Theophylline solutions were freshly prepared from 10-mL ampoules containing 24 Baseline FVR was 47±6 AU in the cannulated arm. In 12 subjects, the effects of two adenosine dosages and four ATP dosages were studied first. FVR of the infused arm during the first and second saline infusions did not significantly differ (47±6 and 53±9 AU, respectively, P=NS; N=12). ATP decreased FVR by 17±12%, 37±11%, 52±7%, and 60±7% for 0.1, 0.3, 1, and 3 ,g ATP* 100 mL forearm . *min-1, respectively (N=12; P<.05 for the three highest dosages). The FVR in the control arm was not significantly affected. In Fig 2, the forearm vascular effects of two equimolar adenosine and ATP dosages (2 and 6 nmol* 100 mL-1 min-1) are compared. Both ATP dosages induced significantly more forearm vasodilation than their equimolar adenosine counterparts (37±11% versus 9±6% for 2 nmol * 100 mL forearm-1 * min-1 and 60±7% versus 21±7% for 6 nmol * 100 mL forearm`* min-'; N=12; P<.05 for both comparisons).
In 6 subjects, the ATP infusions were repeated 45 minutes later. The vasodilator response to ATP did not significantly differ between the two infusion periods: the averaged responses in FVR were -46±8% and -45±10% in the infused arm for the first and second ATP infusions, respectively (P=NS). In the control arm, vascular resistance remained unchanged (averaged response in FVR, 2±5% and 8±14% during the first and second infusion periods, respectively; N=6, P>.1). In the other 6 subjects, the ATP infusions were repeated with concomitant infusion of theophylline. FVRs during the second saline infusion and the theophylline infusion were 54±16 and 54±17 AU, respectively (P=NS, N=6). FVR during theophylline infusion did not differ significantly from FVR during the third saline infusion of the time-control study group (54±17 versus 62±8 AU; P=NS, N=6 for both groups). Thus, theophylline did not significantly affect baseline FVR. Likewise, theophylline did not significantly affect the ATP-induced forearm vasodilator response: the averaged responses in FVR were -38±12% and -38±10% for ATP infusions with saline infusion and theophylline, respectively (P=NS, N=6). In the control arm, no changes in FVR were observed.
Involvement of NO in the ATP-Induced Forearm
Vasodilator Response FBF in the control arm was not affected by the various drug infusions. Fig 3 depicts the effect of each dosage of the three vasodilator substances on FVR in the infused arm before and during L-NMMA infusion. In the infused arm, for each vasodilator substance, a The vascular effects of equimolar dosages of ATP and adenosine, the degradation product of ATP with the highest P1-purinergic receptor agonist activity, demonstrate that Pi-purinergic receptor stimulation hardly contributes to the ATP-induced vasodilation. This view is further supported by the fact that theophylline did not affect the vasodilator response to ATP. Since theophylline has been shown to antagonize the forearm vasodilator response to adenosine,824 the present observation rules out that P1-purinergic receptor stimulation is involved in the ATP-induced forearm vasodilator response. This is in agreement with most in vitro studies.1336-39 In theory, theophylline could have inhibited intracellular phosphodiesterase activity. Since cAMP is thought to be an important second messenger of A2-purinergic receptor stimulation, this effect could have counteracted the Pi-purinergic receptor-antagonizing action of theophylline. This problem has been addressed by others using the forearm vasodilator response to theophylline as a marker of phosphodiesterase inhibition.24,40 They found that theophylline infusions up to 100 ,gg 100 mL`min' did not affect forearm vascular tone but significantly antagonized the adenosine-induced vasodilation. In our study, the same theophylline dosage was used without any effect on vascular tone. Therefore, it is very unlikely that inhibition of phosphodiesterase has contributed to the results.
In view of the extensive literature on in vitro vascular effects of ATP, the exclusion of P1-purinergic receptor involvement strongly suggests the existence of the P2y-purinergic receptor in the human forearm vascular bed.3 However, the involvement of a recently suggested "pyrimidine receptor" cannot be excluded. The vasodilator response to acetylcholine was reduced significantly by L-NMMA, indicating that the dosage of L-NMMA used in this study is able to inhibit NO synthase significantly. In contrast, the ATP-induced vasodilator response could not be inhibited by concomitant L-NMMA infusion, despite a similar degree of vasodilation induced by ATP and acetylcholine. This finding supports the argument that NO does not significantly contribute to ATP-induced vasodilation. The SNP-induced forearm vasodilation was not affected by concomitant L-NMMA infusion, ruling out the possibility that agonist-induced vasodilation was affected by L-NMMA-evoked precontraction. During the second series of SNP infusions, FVR in the control arm increased temporarily. A possible systemic effect of the concomitant L-NMMA infusion is not likely, because it was not observed in the ATP and acetylcholine groups and because FVR in the control arm returned to baseline levels during the last administration of SNP with concomitant L-NMMA infusion. Whatever the cause might be, it did not seriously affect the results obtained from the infused arm, since it was only a small change in FVR that did not significantly differ from FVR fluctuations in the control arm during SNP administration with concomitant saline infusion.
In all three groups, L-NMMA induced a significant increase in FVR, confirming that L-NMMA in the dosages used was able to inhibit baseline NO production. 26 This effect of L-NMMA differed between the three groups, indicating an influence of agonist pretreatment on NO synthase activity. During the second L-NMMA infusion, 10 minutes after the lowest agonist infusion, these between-group differences were more pronounced, supporting this view (see Table 2 ). Since SNP does not stimulate NO synthase, the effect of L-NMMA in the SNP group can be regarded as unaffected by the previous infusions of SNP. In the acetylcholine group, the vasoconstrictor response to L-NMMA was significantly higher than in the SNP group, indicating that NO synthase was still activated 50 minutes after the last acetylcholine infusion, although FVR had returned to baseline levels. In the ATP group, L-NMMA-induced vasoconstriction was similar to that observed in the SNP group during both the first and second L-NMMA infusions. In combination with the lack of effect of L-NMMA on ATP-induced vasodilation, these results indicate that ATP does not stimulate NO synthase activity in the human forearm vascular bed. In theory, kinetic differences between acetylcholine and ATP could explain the between-group differences for the effect of L-NMMA on FVR. However, both acetylcholine and ATP have a short half-life of a few seconds because of rapid degradation by choline esterase and ectonucleotidases, respectively. Furthermore, both substances induced a similar amount of vasodilation, and in both the ATP and acetylcholine groups, FVR had returned to baseline levels before L-NMMIA was infused. Therefore, kinetic differences between the two agonists are not able to explain the divergent effect of L-NMMA in the acetylcholine and ATP groups. Probably, NO synthase remained activated after acetylcholine infusion without continuous muscarine receptor stimulation.
One might argue that the group differences in L-NMMA-evoked contractions reflect group differences in NO synthase sensitivity to L-NMMA. However, this would assume a positive correlation between L-NMMA-induced vasoconstriction and the inhibitory effect of L-NMMA on the forearm vasodilator response to acetylcholine and ATP. In contrast, a negative correlation was observed. Therefore, we believe that our results are not relevantly confounded by group differences in NO synthase sensitivity to L-NMMA. In addition, the existence of a confounding factor is not likely, because the study groups 
